Showing results (201-210 of 223) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple MyelomaJennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Frontiers in Oncology|January 3, 2022
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical EfficacyHoyoung M Maeng, Brittni N Moore, Hadi Bagheri, et al.
Journal of Translational Medicine|November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.
Cell Reports|March 22, 2018
Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture SystemRaul Vizcardo, Nicholas D Klemen, S M Rafiqul Islam, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Translational Medicine|March 29, 2011
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"Paolo A Ascierto, Eleonora De Maio, Stefano Bertuzzi, et al.
Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Pageof 23